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Abstract Cisplatin belongs to platinum-based drugs and is widely used in cancer chemotherapy. Ototoxicity is one
of the major dose limiting side-effects of cisplatin. For toxicity to occur cisplatin must first be transported from the
bloodstream into cochlear cells. Three copper transporters are considered pathways for regulating the uptake and
translocation of cisplatin into cells: Ctr1, ATP7A and ATP7B. Our recent study with cochlear organotypic cultures
shows that cochlear hair cells can be destroyed by cisplatin at low concentrations from 10μm to 100μn. However,
high doses of cisplatin cannot damage hair cells, maybe due to intrinsic feedback reactions that increase export of
platinum by ATP7B when the platinum concentration is high in extracellular space. Cimitidine is a specific copper
transporter inhibitor that can block the entrance of copper and platinum, and may prevent cisplatin-induced cochlear
hair cell injury. To evaluate this hypothesis, we treated cochlear organotypic cultures with cisplatin (10 μm or 50 μm)
alone, or cisplatin combined with cimitidine at concentrations ranging from 10-2000 μm for 48 hours. cisplatin at 10
μm damaged about 20% hair cells. In contrast, when cimitidine (10 μm, 100 μm and 2000 μm) was added to the
culture, near 100% cochlear hair cell survived. At higher concentration (50 μm), cisplatin destroyed about 80% of
cochlear hair cells. However, 100 μmcimitidine rescued about 50% hair cells from cisplatin damage, and 2000μm
cimitidine protected about 80% hair cells. The data of western blot showed that CTR1 and ATP7B expressions were
increased in cisplatin treated cochlear tissue, but cimitidine significantly reduced CTR1 and ATP7B. In addition,
ATP7A expression was depressed a little after cisplatin treatment. Considering that Ctr1 is involved in copper and
platinum influx, but the ATP7A and ATP7B are copper export transporters, the results suggest that cimitidine can
effectively block the entrance by copper transporters and stop the influx of cisplatin.
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Introduction
Cisplatin is one of the most widely used chemothera⁃
peutic agents for the treatment of various malignant
tumors. The antitumor effects of cisplatin largely arise
from intrastrand and interstrand cross linking of DNA
leading to G2 cell cycle arrest thereby blocking tumor
proliferation .1, 2 Cisplatin also induces a complete
blockage at the S phase of the cell cycle inhibiting total
mRNA transcription .3
In addition to its potent anti-tumor actions, cisplatin
is highly toxic to the kidney, liver, nervous system,
bone marrow, inner ear, etc. 4-10 The ototoxic effects of
cisplatin produce significant hearing loss and permanent
destruction of cochlear hair cells and spiral ganglion
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neurons (SGNs). 11-14 Cisplatin-induced damage to
cochlear hair cells (HCs) is initiated in outer hair cells
(OHC) followed by inner hair cells (IHC). The HC
damage begins at the basal turn of the cochlea and gradu⁃
ally spreads to the apex in vivo. 12, 14, 15 However, cisplat⁃
in destroys both OHCs and IHCs evenly through the
entire length of the cochlea in vitro. 13 Besides the damage
to HCs, cisplatin also damages SGNs in the modiolus,
and the marginal epithelium on the stria vascularis .12
Therefore, HCs, SGNs and stria vascularis are three
major targets of cisplatin toxicity in the cochlea. 12, 14
The ototoxic mechanisms of cisplatin involve multiple
factors, such as generation of highly toxic free radicals
and reactive oxygen species (ROS) with reduction of
antioxidant enzymes, 12, 16 destruction of DNA ,17damage
of mitochondria, 8 activation of caspase cascade, 11, 12, 14, 18
and activation of p53. 18, 19 Although a complicated
network of apoptotic signals is involved in cisplatin
ototoxicity, the major apoptotic pathway induced by
cisplatin in the cochlea is initiated from cell death
receptors on the cell membrane, and then converged
to p53 signaling pathway to complete the programmed
self-destruction finally .11, 12, 14, 18, 19
For toxicity to occur cisplatin must first be transported
fromthebloodstreamintocells.Cisplatincanbe activated
once it enters the cytoplasm when the chloride atoms on
cisplatin are displaced by water molecules. The aquatic
cisplatin becomes potent electrophile and then react
with nucleic acid to target DNA. In addition, previous
studies have demonstrated that when cisplatin is trans⁃
ported into the cell, it can bind with glutathione, and
then becomes a cisplatin-glutathione complex to exert
its toxic effects 20. Therefore, the entry of cisplatin is the
first important step responsible for its intracellular
toxic effects.
The pathways that regulate the uptake and transloca⁃
tion of cisplatin into HCs, SGNs, and cochlear support⁃
ing cells are poorly understood. However, research
evidence suggests that cisplatin uptake is mediated
by copper transporters that mediate copper and plati⁃
num homeostasis in the cell. 12, 14, 21-23 Cells tightly regu⁃
late copper homeostasis through three copper transport⁃
ers, Ctr1, ATP7A and ATP7B. Ctr1 imports copper and
platinum-basedcompoundssuchascisplatin, carboplatin,
and oxaliplatin into the cell. 21 ATP7A and ATP7B are
copper exporters which eject the copper and plati⁃
num-based compounds from cytoplasm. 22, 23, 24 Cells
over expressing ATP7B show increased efflux of cisplatin
and carboplatin from the cytoplasm and reduced accu⁃
mulation of these compounds .24, 25, 26 These results
suggest that ATP7B is important in drug efflux and
cisplatin resistance. In contrast, cells that over express
ATP7A accumulate large amounts of cisplatin in vesicles.
These cells are also resistant to toxicity presumably by
preventing escape of platinum to potentially lethal
targets such DNA.27Therefore, Ctr1, ATP7A, and
ATP7B regulate the uptake and extrusion of copper and
platinum-based compounds.
The efficiency of copper and/or platinum input or
output depends on the requirement of the cell and the
level of intracellular copper/platinum. Cells may detect
intracellular and extracellular copper/platinum levels
for the appropriate regulation. If the level of copper in
the cells is high, cell can enhance its export; otherwise
it may gain its import. For example, high extracellular
copper leads to the endocytosis of Ctr1 from the mem⁃
brane and subsequent protein degradation. This reduces
the uptake of copper/platinum from the extracellular
environment preventing excess copper uptake into the
cytoplasm. 24-28 These important findings suggest that
high level of extracellular copper/platinum is detect⁃
able by the cell, which causes Ctr1 to rapidly withdraw
from the membrane into the cytoplasm where Ctr1 is
quickly degraded; and that this negative feedback
mechanism reduces the uptake of copper/platinum and
reduces its toxicity.
In order to test if HCs can also regulate input and
output of cisplatin to achieve a self-defense, post-natal
cochlear organotypic cultures were treated with various
doses of cisplatin for 24 or 48 hours. The missing of
HCs and the changes in expression of copper transporters
by cisplatin treatment was evaluated in present study.
In addition, the protective effects of copper transporter
inhibitor, cimetidine was also evaluated to illuminate
the possibility of regulating copper transporters.
Materials and Methods
Cochlear organotypic cultures and cisplatin treat⁃
ment
Rat pups (Sprague Dawley) at postnatal day 3 were
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used for this project. The cochlea was carefully
removed in Hank’s Balanced Salt Solution (1X GIBCO,
14175, Psisley, U.K.). The lateral wall of the cochlea
was dissected away and the whole basilar membrane
containing the organ of Corti and spiral ganglion
neurons was taken as a flat surface preparation under a
microscope. A drop (12 μl) of rat tail collagen (Type 1,
BD Biosciences, 4236 Bedford, MA), 10×basal medium
eagle (BME, Sigma B9638), 2% sodium carbonate, 9:1:
1 ratio) was placed in the center of a 35 mm diameter
culture dish (Falcon 1008, Becton Dickinson) and allowed
to gel at room temperature. After the gel became gelled,
1.2 ml of serum-free medium consisting of 2 g bovine
serum albumin (BSA, Sigma A-4919), 2 mlSerum-Free
Supplement (SigmaI-1884),4.8mlof20%glucose (Sigma
G-2020), 0.4 ml penicillin G (Sigma P-3414), 2 ml of
200 mM glutamine (Sigma G-6392), and 190.8 ml of
1X BME (Sigma B-1522) were added into the dish. The
cochlear tissues were placed on the surface of the colla⁃
gen gel. The cochlear explants were placed in an incu⁃
bator (Forma Scientific, #3029) and maintained at
37℃ in 5% CO2 overnight. On the second day, the
cochlear tissue was treated with various experimental
conditions for 24 or 48 hours.
Experimental conditions
After overnight recovery, cochlear explants were
treated with various concentrations of cisplatin (0, 10,
50, 100, 400, and 1000 μm) for 24 or 48 h for cisplatin
dose response evaluation.
To test if copper transporter blocker, cimetidine can
prevent entry of copper transporter to protect cochlear
hair cells against cisplatin injury, cochlear explants
were treated with different concentrations of cimetidine
(10, 100, 2000, and 4000 μm) for 24 or 48 h with or
without cisplatin (10, 50 μm).
Histology
In the end of the experiment, the cochlear tissue was
fixed with 10% formalin in PBS for 4 hours. After fixa⁃
tion, specimens were rinsed in 0.1M PBS, immersed in
TRITC-labeled phalloidin (Sigma P1951, 1:200) in
PBS for 30 min. Specimens were rinsed three times in
0.1M PBS and mounted on glass slides in glycerin.
Under a fluorescent microscope (BioRad MRC1024),
specimens were examined with appropriate filter for
TRITC (absorption: 544 nm, emission: 572 nm). The
number of missing OHC and IHC for each 0.24-mm
segment was counted through entire the length of the
organ of Corti. A cochleogram was constructed by plot⁃
ting the percent IHC loss and OHC loss as a function of
percent distance from the apex of the cochlea. To aid in
the analysis, average cochleogram was constructed from
specimens for each experimental condition. Because
each end of the basilar membrane was damaged during
surface preparation, comparisons between HC counts
were made between 20% and 80% of the distance from
the apex of the cochlea.
Western Blotting
Western blots were used to assess the level of protein
expression of Ctr1, ATP7A and ATP7B from cochlear
explants exposed to the various experimental conditions
described above (i.e., dose-damage response experi⁃
ments: control, 10, 50, 400 and 1000 μm cisplatin;
otoprotective experiments: control, cisplatin (10 and
50μm), cimetidine (2000μm, and cisplatin + cimeti⁃
dine). To provide sufficient protein for analysis, 20
cochlear explants were used for each treatment condi⁃
tion. Protein concentrations were measured by the
Bradford assay (Bradford, 1976). Proteins from crude
lysates (40μg protein) were separated by SDS-polyacryl⁃
amide gel electrophoresis using precast 12.5%NuPAGE
gels (Invitrogen) at 200V according to the manufacturer’
s guidelines. Proteins were transferred to polyvinylidene
difluoride membranes, blocked with 0.2% I-Block
(AppliedBiosystems,FosterCity,CA),0.1% polyethylene
glycol sorbitan monolaurate (Tween 20, Sigma) in PBS,
and probed by incubation for 1 h with primary anti⁃
bodies for Ctr1, ATP7B, or ATP7A. Membranes were
washed in PBS-Tween (0.1% Tween 20) and incubated
for 1 h with an appropriate HRP-conjugated secondary
antibody (Pierce Chemical Co., Rockford, IL) in blocking
buffer. Afterwashing inPBS-Tween,antibody complexes
were visualized by chemiluminescence using Super⁃
Signal West Femto Maximum Sensitivity Substrate
(Pierce) and a Fuji LAS-1000 Plus chemiluminescence
imager (Tokyo). Figure panels were made by digitally
assembling the relevant lanes with Adobe Photoshop
software. Background corrected bands (NIH Image J
software) were normalized against bands obtained by strip⁃
pingthemembranewith25mMglycine(BioRad,Hercules,
CA), pH 2.0, 1% lauryl sulfate (Fisher Scientific,
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Pittsburgh, PA) and reprobing with an antibody
against glyceraldehyde 3 phosphate dehydrogenase
(GAPDH, Millipore). GAPDH was used as a loading
control as the housekeeping protein to compare with
specific bands of the Ctr1, ATP7B or ATP7A. To quan⁃
tify the changes in Ctr1, ATP7B or ATP7A expression,
we calculated the ratio of the relative density of Ctr1,
ATP7B or ATP7A bands compared to the GAPDH.
The relative density ratio of Ctr1:GAPDH, ATP7B:
GAPH, ATP7A: GAPH in the control condition was set
at 1.0, and the ratios of densities corresponding to the
other treatment conditions were normalized accordingly.
Results
HC degeneration after cisplatin treatment
After 24 hours of culturing with various doses of cisplatin, there was no HC loss. However, the stereocilia bun-
dle showed disarray or missing in low dose cisplatin treated cochleae (10 μm, 50 μm and 100 μm). In contrast, the
stereocilia bundle presented normal when the concentration of cisplatin exceeded 400 µM (Figure 1).
.
Fig. 1 After 24 h of cisplatin treatment with various doses showing no HC loss. However, disarrayed stereocilia
bundles are seen in low dose cisplatin treated cochleae (10 μm, 50 μm, and 100 μm), while the stereocilia bundle
presents normal in high concentration cisplatin treated cochlear explants (400 μm and 1000 μm). Arrowheads point
to pictures of HCs at the corresponding locations on the cochlear basilar membrane near the apical turn.
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After 48 hours of culturing, hair cell damage appeared in lower dose cisplatin treated cochlea (10 μm, 50 μm, and
100 μm). However, most HCs were intact with the high doses of cisplatin treatment (400 μm and 1000 μm, Figure 2).
The cochleograms revealed an unusual dose-damage response relationship: hair cell loss increased up to 50 μm
cisplatin, but then dropped off precipitously at doses higher than 100 μm.
Fig. 2 After 48 h of cisplatin treatment. HCs loss is seen in low dose treated cochlear explants (10 μm, 50 μm, and
100 μm). However, when the concentration of cisplatin excess 400 μm, HCs are intact. Arrowheads point to pictures
of HCs at the corresponding locations on the cochlear basilar membrane near the apical turn.
Changes in expression of copper transporters following cisplatin treatment
Western blots were used to quantify the changes in the level of protein expression of Ctr1, ATP7B, and ATP7A
following exposure to cisplatin at various concentrations (0, 10, 50, 400 and 1000 μM cisplatin). As shown in Fig. 3,
the expression of Ctr1 was relatively unchanged by cisplatin doses that induced appreciable hair cell loss (i.e., 10
and 50 μM), whereas there was a modest (~3-fold) increase in the expression of Ctr1 at the high cisplatin doses
(400 μM and 1000 μM). In contrast, a dramatic cisplatin dose-dependent increase was detected in the expression
of ATP7B. Compared to the control condition, there was an over 120-fold increase in the expression of ATP7B
following 1000 μM cisplatin exposure. The expression of ATP7A was increased visibly at dose of 50 μM that
induced hair cell loss, while a great reduction was seen when the concentration of cisplatin exceeded 400μM (Fig. 3).
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HCs degeneration after cimetidine treatment
To determine the safest endurance limit of cimetidine to the HCs, the specimens were observed along the entire
length of the organ of Corti for different doses of cimetidine treatment. Figure 4 shows the morphological changes in
pattern of steriocilia of HCs 48 h after cimetidine treatment at various doses ranging from 10 to 4000 μm. The pattern
of stereocilia bundle on HCs presented normal in 10 miuwm, 100 μm, and 2000 μm cimetidine treated cochleae (Fig.
4A, 4B, and 4C). However, when the concentration of cimetidine reached 4000 μm, the steriocilia of hair cells were
disorganized (Fig. 4D), despite the fact that there was no hair cell missing, suggesting that 48 h treatment of 4000 μm
cimetidine under culture condition may cause potential injury to HCs, whereas 2000 μm cimetidine treatment may be
safe to HCs.
Fig. 4 Microphotographs of representative cultures labeled with TRITC-conjugated phalloidin. (A) cochlear explants
treated with 10 μm cimetidine for 48 h. (B) cochlear tissue treated with 100 μm cimetidine for 48 h. (C) cochlear
explants treated with 2000 μm cimetidine for 48 h. (D) cochlea treated with 4000 μm cimetidine for 48 h. Note that
treatment with 4000 μm cimetidine results in disarrayed stereocilia bundle.
Fig. 3 Western blots showing typical pattern of protein
expression of copper transporters, Ctr1, ATP7B and
ATP7A in cochlear cultures treated with various doses of
cisplatin for 48 h. Note that the expression of copper
importer Ctr1 is relatively unchanged. However, the
expression of copper exporter, ATP7B is greatly increased
at high dose cisplatin treated cochlear explants (400 μM
and 1000 μM). The expression of ATP7A is increased
only in 50 μM cisplatin treated cochlear tissue.
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Protective effects of cimetidine to HCs against cisplat⁃
in
Figure 5 and figure 6 show the protective effect of
cimetidine in preventing cisplatin injury to HC. The
addition of 2000 μm cimetidine to the cochlear cultures
enhanced HC survival. Treatment of cultures with 10
μmcisplatin alone damaged about 20% of the HCs (Fig.
5A, 6A). When the cultures were treated with cisplatin
plus cimetidine (10, 100, or 2000 μm), nearly 100% of
HCs survived (Fig. 5B, 5C, and 5D. Fig. 6A). Treatment
of cochlear cultures with 50 μm cisplatin resulted in
approximately 90% HCs loss (Fig. 5E. Fig. 6B) and addi⁃
tion of 10 μm cimetidine did not protect HC (Fig. 5F.
Fig. 6B). However, when the cultures were treated with
cisplatin plus 100 μm of cimetidine, HC loss decreased
to about 50% (Fig. 6B). When the concentration of
cimetidine was increased to 2000 μm, HC loss
decreased to 20% (Fig. 5G, 5H. Fig. 6B).
Fig. 5 Microphotographs of phalloidin-labeled cochlear organo⁃
typic cultures. (A) cochlear explants treated with 10 μm cisplatin
for 48 h with mild HC loss. (B) Intact HCs when the cochlear
culture is treated with 10 μm cisplatin plus 10 μm cimetidine for
48 h. (C) No HC missing when cochlear explants is treated with 10
μm cisplatin plus 100 μm cimetidine for 48 h. (D) HCs present
normal when treated with 10μm cisplatin plus 2000μm cimetidine
for 48 h. (E) cochlear explants treated with 50 μm cisplatin for 48
h with severe HC loss. (F) HCs cannot be rescued when the cochle⁃
ar tissue is treated with 50 μm cisplatin plus 10μm cimetidine for
48 h. (G) HC loss is decreased to about 50% when treated with 50
μm cisplatin plus 100 μm cimetidine for 48 h. (H) cochlear
explants treated with 50 μm cisplatin plus 2000 μm cimetidine
showing HC survival of about 80% (Fig. 5G, 5H).
Fig. 6 Protective effects of cimetidine to HCs when co-adminis⁃
trated with cisplatin. The density of surviving HC is measured
between 20% and 80% of the distance from the apex of the cochlear
explants (n=6 per condition) that have been exposed for 48 h to 10
μm or 50 μm cisplatin with or without cimetidine (10, 100 or 2000
μm). HC density is reduced by about 20% when treated with 10
μm cisplatin, but most HCs are intact when cimetidine (10, 100,
or 2000 μm) is added (A). More than 80% HCs are destroyed by
50 μm cimetidine, but increasing the dose of cimetidine to 100
μm results in an increase of survival HC to 50% , while adding
2000 μm cimetidine rescues about 80% of HCs. Cimetidine at 10
μm does not protect the HC from cisplatin damage (B).
Changes in expression of copper transporters follow⁃
ing cisplatin/cimetidine treatment
Western blots showed that cisplatin treatment alone
increased the expression of Ctr1 and ATP7B, while
cimetidine administered alone reduced the expression in
both Ctr1 and ATP7B. However, the expression of
ATP7A showed little changed (Fig. 7). When the cochlear
explants were treated with cisplatin plus cimetidine, the
expression of Ctr1 and ATP7B was still lower than
normal (Fig. 7).
Discussion
The ototoxic effects of cisplatin in vivo study often
result in HC lesions with OHC damage being more
severe than IHC, and the HC loss progresses along a
base to apex gradient, 12,14,15which is very similar to most
ototoxic reagents, such as aminoglycoside antibiotics.
However, an unusual hair cell lesion was found in cisplatin
treated cochlear cultures in that the IHC and OHC
destruction is nearly the same along the entire length of
the cochlea. This may suggest that when the cochlear
tissue is displaced into culture conditions, the cellular
response to cisplatin ototoxicity is different from in vivo
conditions .
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Copper transporters are the major cellular entrance of
copper and platinum .21-28 Information from cancer
research has revealed that cells can adjust the copper/
platinum import and export natively by action of copper
transporters. 22-28 In vitro studies on nephrotoxicity of
cisplatin have confirmed that the concentrations of
cisplatin up to 1.67 mM maintain a dose-dependent
manner. 29 In our recent study, a dose-dependent
response was seen in RB142 cell lines in various cisplatin
concentrations up to 1000 μm. 13 The ototoxic effect of
cisplatin in Zebrafish is also dose-dependent at high
concentrations up to 400 μm. 30 These may indicate that
the chemical property of cisplatin in cellular damage
does not alter at high concentrations. Interestingly, an
incidental finding was disclosed in current study that
when the concentration of cisplatin exceeds 400μm,
HCs show an intrinsic resistance to cisplatin .13 Although
previous reports alleged that cisplatin-induced ototox⁃
icity showed a dose-dependent manner, the highest cispl⁃
atin concentration applied in mammalian cochlear cul⁃
tures was under 10 μg/ml (33.3μm). Therefore, previ⁃
ous dose dependent response of cisplatin was restricted
to the low level of cisplatin.19 In the current study, the
greatest destruction of HCs was found at low concentra⁃
tions ranging from 10 μm to 100 μm. In contrast, high
dose of cisplatin ranging from 400 μm to 1000 μm did
not demolish the HCs. The changes in expression of
copper transporters revealed that high dose cisplatin re⁃
sulted in a significant increase of copper/platinum ef⁃
flux by ATP7B, which effectively decreased the intra⁃
cellular platinum accumulation. Thus, we ascribe the
limited ototoxicity observed at high doses of cisplatin to
a reduction ofitintracellular accumulation via increased
ATP7B-mediated efflux. The dynamic changes inex⁃
pression of ATP7A may reflect the changes in plati⁃
num accumulation by great deal of platinum efflux
caused by ATP7B. However, if the dose of cisplatin is
low, HC may relax vigilance allowing platinum to enter
the cell.
As a potent copper transporter inhibitor, cimetidine
can effectively prevent the action of copper transporters
without interfering with the antitumor effects of cispl⁃
atin. 31 In our recent study, we have demonstrated that
cimetidine has a potential to protect HC against cisplatin
toxicity .13 The similar protective effects have been
repeated in the current study. The result from western
blot in present study further demonstrated that cimeti⁃
dine can play an important role in HC protection. Consid⁃
ering the exporters of copper transporters, ATP7A and
ATP7B were also inhibited by cimetidine. The protec⁃
tive effects of cimetidine to HC should be credited to its
inhibiting the influx of cisplatin through copper trans⁃
porter importer, Ctr1.
Cisplatin ototoxicity seriously affects people’s quality
of life. To prevent the ototoxicity of cisplatin, many strat⁃
egies can be considered for inner ear protection. For
example, antioxidation and anti-apoptosis are partially
efficient in protecting HCs against cisplatin ototoxicity.
However, the premise for those protections must be in
the process of cell degeneration. Therefore, the protec⁃
tive actions in both antioxidation and anti-apoptosis
are limited. The results in the current study by modu⁃
lating copper transporters may lead to development of
a new strategy against cisplatin ototoxicity, which
keeps cisplatin out of the cell by reducing platinum
influx and enhancing platinum efflux.
Fig. 7 Western blots showing protein expression of copper
transporters Ctr1, ATP7B and ATP7A in normal cochlear
explants, cochlear cultures treated with 50 μm cisplatin for 48
h, cochlear explants treated with 2000 μm cimetidine for 48 h,
and a combined treatment of 50 μm cisplatin and 2000 μm
cimetidine for 48 h. Note that the expression of copper importers
Ctr1 and ATP7B are significantly increased by cisplatin treat⁃
ment. In contrast, the expression of both Ctr1 and ATP7B are
greatly decreased by cimetidine treatment. Even with treatment
of 50 μmcisplatin and 2000 μm cimetidine together for 48 h,
the expression of Ctr1 and ATP7B remains lower than normal co⁃
chlear tissue. The expression of ATP7A is slightly changed in
all above conditions.
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